Inlyta (axitinib) — United Healthcare
salivary gland tumor
Initial criteria
- Diagnosis of salivary gland tumor
- Disease is recurrent OR unresectable OR metastatic
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Inlyta therapy
Approval duration
12 months